Risdiplam for Spinal Muscular Atrophy New Drug Application Accepted

  • Child neurology
  • Neuromuscular disease
  • Risdiplam
  • Spinal muscular atrophy

The FDA has accepted new drug application (NDA) and granted priority review for risdiplam (Genentech, San Francisco, CA), an investigational, survival motor neuron-2 (SMN-2) splicing modifier for spinal muscular atrophy (SMA). The FDA is expected to make a decision on approval by May 24, 2020.   

If approved, risdiplam, an orally administered liquid, would be the first at-home administered medicine for people living with SMA. Risdiplam is designed to increase and sustain SMN protein levels both throughout the central nervous system and peripheral tissues of the body. 

In addition to the FIREFISH (NCT02913482) and SUNFISH (NCT02908685) studies included in the NDA submission, risdiplam is being studied in a broad clinical trial program in SMA, with participants ranging from newborns to 60 years old, and includes participants previously treated with SMA therapies. 

Midazolam Nasal Spray for Acute Treatment of Seizure Clusters To Be Available In December 

Previous News Article

FDA Approves Cenobamate for Treatment of Partial-Onset Seizures in Adults

Next News Article
This Month's Issue
MS Minute: Oral Therapies for MS

Neeta Garg, MD; Micheline McCarthy, MD, PhD; and Ameeta Karmarkar, MD

Epilepsy Essentials: Cenobamate

Michelle L. Dougherty, MD, FAAN, FAES

Case Report: Seizure, Fever, Hallucinations, & Vision Loss

Elizabeth Carroll, MD; Asya I. Wallach, MD; Arielle Kurzweil, MD; Steven Frucht, MD; Thomas Berk, MD; Michael Boffa, MD; and Ilya Kister, MD